Glucose tolerance and plasma testosterone concentrations in men. Results of the Asturias Study

Menéndez, Edelmiro; Valdés, Sergio; Botas, Patricia; Delgado, Elias; Abello, Noelia

doi:10.1016/s2173-5093(11)70030-7

Cited by 2 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several epidemiologic studies found an association of low total T levels with increased risk of T2DM, though the association was weak or absent with free T, hinting at SHBG being the primary determinant of the observed correlation[ 54 , 58 , 59 ]. The mechanisms linking low T and worsening of insulin resistance could be loss of skeletal muscle mass, increased fat mass, and effects of T on lipid oxidation and mitochondrial function[ 60 ].…”

Section: Role Of Testosterone In the Management Of Moshmentioning

confidence: 99%

Management of male obesity-related secondary hypogonadism: A clinical update

Shenoy,

Mondal,

Fernandez

et al. 2024

World J Exp Med

View full text Add to dashboard Cite

The global obesity pandemic has resulted in a rise in the prevalence of male obesity-related secondary hypogonadism (MOSH) with emerging evidence on the role of testosterone therapy. We aim to provide an updated and practical approach towards its management. We did a comprehensive literature search across MEDLINE (via PubMed), Scopus, and Google Scholar databases using the keywords “MOSH” OR “Obesity-related hypogonadism” OR “Testosterone replacement therapy” OR “Selective estrogen receptor modulator” OR “SERM” OR “Guidelines on male hypogonadism” as well as a manual search of references within the articles. A narrative review based on available evidence, recommendations and their practical implications was done. Although weight loss is the ideal therapeutic strategy for patients with MOSH, achievement of significant weight reduction is usually difficult with lifestyle changes alone in real-world practice. Therefore, androgen administration is often necessary in the management of hypogonadism in patients with MOSH which also improves many other comorbidities related to obesity. However, there is conflicting evidence for the appropriate use of testosterone replacement therapy (TRT), and it can also be associated with complications. This evidence-based review updates the available evidence including the very recently published results of the TRAVERSE trial and provides comprehensive clinical practice pearls for the management of patients with MOSH. Before starting testosterone replacement in functional hypogonadism of obesity, it would be desirable to initiate lifestyle modification to ensure weight reduction. TRT should be coupled with the management of other comorbidities related to obesity in MOSH patients. Balancing the risks and benefits of TRT should be considered in every patient before and during long-term management.

show abstract

Section: Role Of Testosterone In the Management Of Moshmentioning

confidence: 99%

Management of male obesity-related secondary hypogonadism: A clinical update

Shenoy,

Mondal,

Fernandez

et al. 2024

World J Exp Med

View full text Add to dashboard Cite

show abstract

“…Múltiples estudios epidemiológicos han demostrado que concentraciones bajas de testosterona se asocian con el desarrollo futuro de DM tipo 2 y síndrome metabólico y pueden predecir su aparición. Esto se ha demostrado en estudios transversales (288) Menéndez et al en España encontraron que los varones con concentraciones mas bajas de TT tenían mayor riesgo de presentar intolerancia a la glucosa o diabetes, independientemente de la edad y el IMC (295).…”

Section: Predisposición a Diabetesunclassified

Causas y consecuencias del hipogonadismo en varones con diabetes mellitus tipo 2

Ruiz¹

View full text Add to dashboard Cite

INTRODUCCIÓN 1. Eje hipotálamo-hipofisario-testicular 2. Hipogonadismo 2.1. Definición 2.2. Etiología 2.3. Epidemiología 2.4. Clínica 2.5. Diagnóstico 2.6. Testosterona y edad 2.7. Testosterona y enfermedad cardiovascular 2.8. Testosterona y mortalidad 2.9. Screening de hipogonadismo 3. Diabetes e hipogonadismo 3.1. Prevalencia de hipogonadismo en la diabetes 3.2. Predisposición a diabetes 3.3. Etiopatogenia 3.4. Consecuencias del hipogonadismo en la diabetes 3.5. Estudios de intervención en diabetes 2. BASE RACIONAL Y OBJETIVOS Base racional Objetivos 3. MATERIAL Y MÉTODOS 4. RESULTADOS I. Características de la muestra II. Estudio de hipogonadismo en pacientes diabéticos ABREVIATURAS AAI: anticuerpos anti insulina ACV: accidente cerebrovascular ADA: American Diabetes Association ADAM: Androgen Deficiency in Aging Male ADOS: antidiabéticos orales ALT: alanina aminotransferasa AMSS: Aging Male Symptoms Scale ARA 2: antagonista del receptor de la angiotensina II ASA: American Society of Andrology AST: aspartato aminotransferasa BIA: impedancia bioeléctrica CC: circunferencia de cintura Cr: creatinina Ccr: aclaramiento de creatinina CT: colesterol total CV: coeficiente de variación DE: desviación estándar DHEA: dehidroepiandrosterona DHEAS: dehidroepiandrosterona sulfato DHT: dihidrotestosterona DM: diabetes mellitus DMO: densidad mineral ósea

show abstract

Glucose tolerance and plasma testosterone concentrations in men. Results of the Asturias Study

Cited by 2 publications

References 36 publications

Management of male obesity-related secondary hypogonadism: A clinical update

Management of male obesity-related secondary hypogonadism: A clinical update

Causas y consecuencias del hipogonadismo en varones con diabetes mellitus tipo 2

Contact Info

Product

Resources

About